An Observational Clinical Study to Evaluate COVID-19 Symptoms in Long Hauler Patients Who Participated in K031-120 or K032-120

An Observational Study to Evaluate the Presence of Symptoms After COVID-19 Infection in Patients Who Participated in K031-120 or K032-120 Study (Long Hauler)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04814914

Enrollment

333

Registered

2021-03-24

Start date

2021-03-25

Completion date

2021-05-28

Last updated

2021-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Microbiome, COVID-19, Corona Virus, Corona Virus Disease, Kaleido, Kaleido Biosciences, KB109, Oligosaccharide, Glycan, Microbiome metabolic therapy, MMT, Supportive Self Care, SSC, Telemedicine, K031-120, K032-120

Brief summary

This observational clinical study aims to evaluate the presence of symptoms of COVID-19 infection in patients who participated in K031-120 or K032-120 (long hauler).

Interventions

OTHERKB109 + Self Supportive Care

KB109 is a novel glycan

OTHERSelf Supportive Care (SSC) Alone

Self Supportive Care (SSC) Alone

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Have consented to participate over the telephone * Have been randomized in either the K031-120 or K032-120 study

Exclusion criteria

* Have withdrawn consent from K031-120 or K032-120

Design outcomes

Primary

Measure	Time frame
Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study.	12-weeks from randomization in K031-120 or K032-120

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026